Lilly To Open New Drug Delivery Center in Cambridge

Eli Lilly and Co. plans to establish a new drug delivery and device innovation center in Cambridge, MA. The Lilly Cambridge Innovation Center will allow life science organizations to explore how emerging technologies and connectivity can advance drug delivery and device innovation.
 
The center will serve as a portal for external partnerships and collaboration activities with the company’s existing research facilities in San Diego, New York City and Indianapolis.
 
Construction will begin immediately, with an expected occupancy by the end of 2015. The company plans to hire approximately 30 scientists and engineers and when fully operational, the center will increase the company’s delivery and device R&D space by nearly 50% and increasing staff by 25%.
 
More than half of the company’s pipeline now comprises biologics that require some type of injection. The company expects its revenues from device-enabled products to double by 2020.
 
Lilly chairman, president and chief executive officer John C. Lechleiter, Ph.D., said “The Lilly Cambridge Innovation Center complements a deliberate push by the company to be an industry leader in providing convenient, reliable drug delivery and device innovation. Locating in Cambridge is an important strategic move for achieving this goal, as it provides us access to a concentration of high-caliber academic institutions, cutting-edge life science and technology companies, and some of the world’s leading talent.”